Identification of a role for serum aldo‑keto reductase family 1 member B10 in early detection of hepatocellular carcinoma

Han,Chao; Gao,Lanzhu; Bai,Han; Dou,Xiaoguang

doi:10.3892/ol.2018.9547

Identification of a role for serum aldo‑keto reductase family 1 member B10 in early detection of hepatocellular carcinoma

Authors:
- Chao Han
- Lanzhu Gao
- Han Bai
- Xiaoguang Dou
View Affiliations

Affiliations: Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022, P.R. China
Published online on: October 3, 2018 https://doi.org/10.3892/ol.2018.9547
Pages: 7123-7130
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite improved screening programs, the vast majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage. A lack of effective diagnosis methods for preclinical HCC has resulted in a low rate of early detection. Aldo‑keto reductase family 1 member B10 (AKR1B10) is associated with several cancer types. However, to the best of our knowledge, the diagnostic value of AKR1B10 in early stage HCC is poorly understood. In the current study, the diagnostic performance of serum AKR1B10 in hepatitis B virus/hepatitis C virus (HBV/HCV)‑related liver disorders was evaluated and the unique role of AKR1B10 in diagnosing HCC was assessed. Serum AKR1B10 was detected by sandwich ELISA in 84 patients with HBV/HCV‑related HCC, 74 patients with liver cirrhosis, 29 patients with chronic hepatitis and 30 healthy controls. Serum AKR1B10 and α‑fetoprotein (AFP) levels were analyzed and compared. Elevated levels of serum AKR1B10 were identified in patients with HCC compared with patients with other liver disorders (P<0.05). Compared with advanced and terminal stage HCC, a significant increase in AKR1B10 levels was primarily detected in early and intermediate stage HCC. The sensitivity (81.0%) and specificity (60.9%) for HCC diagnosis with AKR1B10 were high at a cutoff value of 1.51 ng/ml. Conversely, a prominent increase in AFP was observed in advanced and terminal stage HCC. Furthermore, concurrent measurement of serum AKR1B10 and AFP significantly increased sensitivity and negative predictive value for HCC diagnosis. The results presented in the current study strongly indicate AKR1B10 has a unique role as a biomarker for early stage HBV/HCV‑related HCC. Compared with AFP alone, a combination of serum AKR1B10 and AFP increased the diagnostic performance in patients with HCC. In summary, the current results identify a unique role of AKR1B10 in HCC diagnosis.

View Figures

View References

1	Ministry of Health of the People's Republic of China: Diagnosis, management, and treatment of hepatocellular carcinoma (V2011). J Clini Hepatol. 11:1141–1159. 2011.(In Chinese).
2	Global Burden of Disease Cancer C, . Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015. View Article : Google Scholar : PubMed/NCBI
3	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
4	McGlynn KA, Petrick JL and London WT: Global epidemiology of hepatocellular carcinoma: An emphasis on demographic and regional variability. Clin Liver Dis. 19:223–238. 2015. View Article : Google Scholar : PubMed/NCBI
5	Yang X, Gao JY, Wang J and Cheng J: The impact of anti-HBV treatment on the occurrence and recurrence of hepatocellular carcinoma: Focus on Asian studies. Discov Med. 19:89–99. 2015.PubMed/NCBI
6	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
7	Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases, . Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
8	Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y and Nakatsura T: Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 21:10573–10583. 2015. View Article : Google Scholar : PubMed/NCBI
9	Spangenberg HC, Thimme R and Blum HE: Serum markers of hepatocellular carcinoma. Semin Liver Dis. 26:385–390. 2006. View Article : Google Scholar : PubMed/NCBI
10	Aghoram R, Cai P and Dickinson JA: Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. CD002799:2012.
11	Chun S, Rhie SY, Ki CS, Kim JE and Park HD: Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas. Ann Hepatol. 14:882–888. 2015. View Article : Google Scholar : PubMed/NCBI
12	Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnù L, Zoli M, et al: Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 56:1371–1379. 2012. View Article : Google Scholar : PubMed/NCBI
13	Dai M, Chen X, Liu X, Peng Z, Meng J and Dai S: Diagnostic value of the combination of Golgi Protein 73 and alpha-fetoprotein in hepatocellular carcinoma: A meta-analysis. PLoS One. 10:e01400672015. View Article : Google Scholar : PubMed/NCBI
14	Li D, Mallory T and Satomura S: AFP-L3: A new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 313:15–19. 2001. View Article : Google Scholar : PubMed/NCBI
15	Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y and Nagataki S: Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 328:1802–1806. 1993. View Article : Google Scholar : PubMed/NCBI
16	Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, et al: Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 137:110–118. 2009. View Article : Google Scholar : PubMed/NCBI
17	Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME and Sherman M: Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 7:104–113. 2009. View Article : Google Scholar : PubMed/NCBI
18	Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL and Dienstag JL; HALT-C Trial Group, . Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 138:493–502. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G and Schlaak JF: A combination of α-fetoprotein and des-U-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 87:121–131. 2013. View Article : Google Scholar : PubMed/NCBI
20	Pote N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P and Paradis V: Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 62:848–854. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao DF and Cao D: Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem. 283:3418–3423. 2008. View Article : Google Scholar : PubMed/NCBI
22	Wang C, Yan R, Luo D, Watabe K, Liao DF and Cao D: Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem. 284:26742–26748. 2009. View Article : Google Scholar : PubMed/NCBI
23	Cao D, Fan ST and Chung SS: Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem. 273:11429–11435. 1998. View Article : Google Scholar : PubMed/NCBI
24	Conklin D, Prough R and Bhatanagar A: Aldehyde metabolism in the cardiovascular system. Mol Biosyst. 3:136–150. 2007. View Article : Google Scholar : PubMed/NCBI
25	Spite M, Baba SP, Ahmed Y, Barski OA, Nijhawan K, Petrash JM, Bhatnagar A and Srivastava S: Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem J. 405:95–105. 2007. View Article : Google Scholar : PubMed/NCBI
26	Yan R, Zu X, Ma J, Liu Z, Adeyanju M and Cao D: Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int J Cancer. 121:2301–2306. 2007. View Article : Google Scholar : PubMed/NCBI
27	Martin HJ and Maser E: Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem Biol Interact. 178:145–150. 2009. View Article : Google Scholar : PubMed/NCBI
28	Zhong L, Liu Z, Yan R, Johnson S, Zhao Y, Fang X and Cao D: Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels. Biochem Biophys Res Commun. 387:245–250. 2009. View Article : Google Scholar : PubMed/NCBI
29	Crosas B, Hyndman DJ, Gallego O, Martras S, Parés X, Flynn TG and Farrés J: Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: Consequences for retinoid metabolism. Biochem J. 373:973–979. 2003. View Article : Google Scholar : PubMed/NCBI
30	Gallego O, Belyaeva OV, Porte S, Ruiz FX, Stetsenko AV, Shabrova EV, Kostereva NV, Farrés J, Parés X and Kedishvili NY: Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids. Biochem J. 399:101–109. 2006. View Article : Google Scholar : PubMed/NCBI
31	Matkowskyj KA, Bai H, Liao J, Zhang W, Li H, Rao S, Omary R and Yang GY: Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum Pathol. 45:834–843. 2014. View Article : Google Scholar : PubMed/NCBI
32	Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W and Tannapfel A: Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol. 52:220–227. 2010. View Article : Google Scholar : PubMed/NCBI
33	Luo DX, Huang MC, Ma J, Gao Z, Liao DF and Cao D: Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway. Biochem J. 438:71–80. 2011. View Article : Google Scholar : PubMed/NCBI
34	Sato S, Genda T, Hirano K, Tsuzura H, Narita Y, Kanemitsu Y, Kikuchi T, Iijima K, Wada R and Ichida T: Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: Association with serum alpha-fetoprotein and hepatocellular carcinoma. Liver Int. 32:1382–1390. 2012. View Article : Google Scholar : PubMed/NCBI
35	Mori M, Genda T, Ichida T, Murata A, Kamei M, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Ishikawa S, et al: Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk. Hepatol Res. 47:E85–E93. 2017. View Article : Google Scholar : PubMed/NCBI
36	Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, et al: Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol. 22:7569–7578. 2016. View Article : Google Scholar : PubMed/NCBI
37	Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, Auer T, Gamerith G and Loeffler-Ragg J: AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: A clinicopathological study of 168 cases. Liver Int. 31:810–816. 2011. View Article : Google Scholar : PubMed/NCBI
38	Ha SY, Song DH, Lee JJ, Lee HW, Cho SY and Park CK: High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma. Gut Liver. 8:648–654. 2014. View Article : Google Scholar : PubMed/NCBI
39	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association: The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi. 19:13–24. 2011.(In Chinese). PubMed/NCBI
40	Llovet JM, Brú C and Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
41	Bruix J and Sherman M; American Association for the Study of Liver Diseases, . Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
42	Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E and Bernardi M: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol. 34:570–575. 2001. View Article : Google Scholar : PubMed/NCBI
43	Bellissimo F, Pinzone MR, Cacopardo B and Nunnari G: Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 21:12003–12021. 2015. View Article : Google Scholar : PubMed/NCBI
44	Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, Peters BE, Balsanek JG, Ward MM, Giama NH, et al: Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 21:599–606. 2015. View Article : Google Scholar : PubMed/NCBI